EF Hutton analyst Jason Kolbert lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $3 from $23 and keeps a Buy rating on the shares. Marinus announced that its Phase 3 TrustTSC trial evaluating oral ganaxolone for treating seizures associated with tuberous sclerosis complex did not meet the primary endpoint of reducing TSC-related seizure frequency, the analyst tells investors in a research note. The firm removed its estimates for the tuberous sclerosis complex but keeps a Buy rating given the stock’s “distressed valuation.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird
- Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities
- Marinus downgraded to Market Perform from Outperform at JMP Securities
- Marinus Pharmaceuticals downgraded to Hold from Buy at Truist
- Marinus notes TrustTSC trial misses primary endpoint, to evaluate alternatives